Boyer S., Marcellin F., Ongolo-Zogo P., Abega S. C., Nantchouang R., Spire B., Moatti Jean-Paul. (2009). Financial barriers to HIV treatment in Yaounde, Cameroon : first results of a national cross-sectional survey. Bulletin of the World Health Organization, 87 (4), p. 279-287. ISSN 0042-9686.
Titre du document
Financial barriers to HIV treatment in Yaounde, Cameroon : first results of a national cross-sectional survey
Boyer S., Marcellin F., Ongolo-Zogo P., Abega S. C., Nantchouang R., Spire B., Moatti Jean-Paul
Source
Bulletin of the World Health Organization, 2009,
87 (4), p. 279-287 ISSN 0042-9686
Objective To assess the extent to which user fees for antiretroviral therapy (ART) represent a financial barrier to access to ART among HIV-positive patients in Yaounde, Cameroon. Methods Sociodemographic, economic and clinical data were collected from a random sample of 707 HIV-positive patients followed up in six public hospitals of the capital city (Yaounde) and its surroundings through face-to-face interviews carried out by trained interviewers independently from medical staff and medical questionnaires filled out by prescribing physicians. Logistic regression models were used to identify factors associated with self-reported financial difficulties in purchasing ART during the previous 3 months. Findings Of the 532 patients treated with ART at the time of the survey, 20% reported financial difficulty in purchasing their antiretroviral drugs during the previous 3 months. After adjustment for socioeconomic and clinical factors, reports of financial difficulties were significantly associated with lower adherence to ART (odds ratio, OR: 0.24; 95% confidence interval, CI: 0.15-0.40; P < 0.0001) and with lower CD4+ lymphocyte (CD4) counts after 6 months of treatment (OR: 2.14; 95% CI: 1.15-3.96 for CD4 counts < 200 cells/mu l; P= 0.04). Conclusion Removing a financial barrier to treatment with ART by eliminating user fees at the point of care delivery, as recommended by WHO, could lead to increased adherence to ART and to improved clinical results. New health financing mechanisms based on the public resources of national governments and international donors are needed to attain universal access to drugs and treatment for HIV infection.
